Masaaki Motoori

8PUBLICATIONS
9CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Nov 07, 2025
Long-Term Survival of Two Versus Three Courses of Preoperative Cisplatin and Fluorouracil Plus Docetaxel for Locally Advanced Esophageal Cancer: A Multicenter Randomized Phase II Trial.

Takahito Sugase, Hiroshi Miyata, Takashi Kanemura

|Jul 03, 2025
Prognostic factors for patients with esophageal cancer who achieve pathological complete response in the primary tumor after upfront chemotherapy or chemoradiotherapy.

Masaaki Motoori, Koji Tanaka, Hiroshi Miyata

|May 04, 2023
Chemoradiotherapy versus triplet chemotherapy as initial therapy for T4b esophageal cancer: survival results from a multicenter randomized Phase 2 trial.

Makoto Yamasaki, Hiroshi Miyata, Kotaro Yamashita

|Dec 09, 2022
The impact of weight loss during neoadjuvant chemotherapy on postoperative infectious complications and prognosis in patients with esophageal cancer: exploratory analysis of OGSG1003.

Shu Aoyama, Masaaki Motoori, Makoto Yamasaki

|May 05, 2022
Risk Factors for Para-Aortic Lymph Node Metastasis in Esophagogastric Junction Cancer: Results from a Prospective Nationwide Multicenter Study.

Masaaki Motoori, Yukinori Kurokawa, Hiroya Takeuchi

|Feb 10, 2022
Multicenter randomised trial of two versus three courses of preoperative cisplatin and fluorouracil plus docetaxel for locally advanced oesophageal squamous cell carcinoma.

Tomoki Makino, Makoto Yamasaki, Koji Tanaka

Pageof 2

Frequent Collaborators

4 joint publications

Tomoki Makino

2 joint publications

Yutaka Kimura

2 joint publications

Koji Tanaka

1 joint publications

Atsushi Takeno